 |
|
 |
|
Anchor Therapeutics is pioneering a new class of drugs called pepducins. Pepducins are a breakthrough approach to targeting G protein coupled receptors (GPCRs) on the inside surface of the cell membrane, dramatically expanding the GPCR frontier. GPCRs are critically involved in a wide variety of serious illnesses, including inflammation, cancer, metabolic CNS disorders and cardiovascular disease. Pepducin technology represents an exciting new area of research directed towards a well-validated class of drug targets.
|
|
 |